Plain-language summaries of the peptide and compound literature: mechanisms, trial data, comparisons and lab practice, with sources cited.
203 articles · 21 compound hubs · 9 subject areas
Anabolic Research
Testosterone propionate is the shortest commonly used testosterone ester with a 1–3 day half-life. Research overview of its pharmacokinetics, use in acute androgen studies, and comparison to long-acting esters.
5 min read
Anabolic Research
Testosterone cypionate and enanthate are both long-acting testosterone esters. This research comparison covers their pharmacokinetic differences, bioequivalence data, and which is preferred for specific research applications.
6 min read
PCT & Support
Testosterone enanthate is the most widely researched testosterone ester in clinical and preclinical studies. Research overview covering pharmacokinetics, androgen receptor signaling, anabolic mechanisms, and research protocols.
8 min read
Weight Loss & GLP-1
A mechanistically rational weight loss research stack combining semaglutide, retatrutide, HGH Fragment 176-191, and MOTS-c — covering appetite suppression, thermogenesis, lipolysis, and metabolic enhancement in one protocol.
7 min read
Weight Loss & GLP-1
T3 (triiodothyronine, liothyronine) is the active thyroid hormone that drives basal metabolic rate. Research overview covering thyroid hormone receptor signaling, thermogenesis, metabolic effects, and protocols for metabolic research.
8 min read
Research Science
Clenbuterol is a beta-2 adrenergic agonist with thermogenic and anabolic properties studied in preclinical models. Research overview covering β2-AR signaling, adipose thermogenesis, skeletal muscle effects, and research protocols.
8 min read
Peptides & Recovery
HGH Fragment 176-191 (AOD-9604) is a modified C-terminal HGH peptide that activates lipolysis without IGF-1 elevation or growth effects. Research overview of its lipolytic mechanism and adipose tissue studies.
7 min read
Weight Loss & GLP-1
A mechanistic deep-dive into triple GIP/GLP-1/glucagon receptor co-agonism — why each receptor contributes distinct weight loss and metabolic effects, and why their combination is synergistic rather than merely additive.
8 min read
Weight Loss & GLP-1
Deep analysis of the NEJM Phase 2 retatrutide trial (Jastreboff 2023) — 24% weight loss at 48 weeks, dose-response data, glycemic outcomes, and what the results mean for obesity pharmacotherapy research.
7 min read
Peptides & Recovery
Head-to-head research comparison of retatrutide (triple agonist) vs semaglutide (GLP-1 agonist) — mechanism differences, weight loss magnitude, glycemic control, side effect profiles, and research protocol selection.
7 min read
Peptides & Recovery
Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — producing 24–26% body weight loss in Phase 2 trials. Research overview of structure, mechanism, and clinical data.
8 min read
Weight Loss & GLP-1
How semaglutide controls blood glucose through GLP-1R-mediated insulin secretion, glucagon suppression, and gastric emptying slowing — with clinical trial HbA1c data and mechanistic analysis.
8 min read
Weight Loss & GLP-1
A comprehensive overview of the GLP-1 receptor agonist drug class — mechanism, clinical evolution from exenatide to semaglutide, and the expanding role of GLP-1R signaling in metabolic disease, cardiovascular health, and neuroscience.
8 min read
Weight Loss & GLP-1
A research-focused analysis of semaglutide's adverse effect profile — nausea, thyroid C-cell findings, pancreatitis signal, and rare events — with mechanistic explanations from GLP-1R pharmacology.
8 min read
Weight Loss & GLP-1
Semaglutide requires gradual dose escalation to minimize GI side effects. This guide covers escalation schedules used in clinical trials and their rodent-equivalent adaptations for research protocols.
6 min read
Weight Loss & GLP-1
Comparing semaglutide administration via pharmaceutical auto-injector pen vs. research-grade vial reconstitution — accuracy, flexibility, storage, and which is appropriate for laboratory research protocols.
6 min read
Peptides & Recovery
Ozempic, Wegovy, and Rybelsus are all semaglutide. This research guide explains the difference — dose, indication, formulation — and what researchers need to know when selecting the appropriate form.
6 min read
Peptides & Recovery
Semaglutide produces 15–17% body weight loss via CNS appetite suppression, slowed gastric emptying, and altered food reward signaling. This deep-dive covers every mechanism behind GLP-1 induced weight loss.
8 min read
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer